- Conditions
- Stage IV Lung Adenocarcinoma
- Interventions
- Certolizumab, cisplatin, pemetrexed
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 479
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Danirixin 35 mg tablets, Placebo, Metered dose inhaler (MDI) sensor device, Rescue medication
- Drug · Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 76 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • San Diego, California • Torrance, California + 8 more
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Laboratory Biomarker Analysis, Leucovorin Calcium, Levoleucovorin, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Questionnaire Administration, Therapeutic Hydrocortisone, Thioguanine, Vincristine Sulfate
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2034
- U.S. locations
- 184
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 145 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Bromefenac, Blink
- Drug
- Lead sponsor
- Bp Consulting, Inc
- Network
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- 140 East 80th Street New York, NY 10075, New York
- Conditions
- Esophagoscopy Techniques, Colonoscopy
- Interventions
- EGD-assisted administration of colonoscopy prep, Control Group received standard prep by oral administration
- Procedure
- Lead sponsor
- Rockford Gastroenterology Associates
- Other
- Eligibility
- Not listed
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- Rockford, Illinois
- Conditions
- Localized Osteosarcoma, Metastatic Osteosarcoma
- Interventions
- Cisplatin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate, Peginterferon Alfa-2b, Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery
- Drug · Biological · Other + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 5 Years to 40 Years
- Enrollment
- 1,334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2022
- U.S. locations
- 186
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 132 more
- Conditions
- B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia
- Interventions
- Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Venetoclax, Vincristine Sulfate
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Osteoarthritis of the Knee, Traumatic Arthritis of the Knee
- Interventions
- Total knee arthroplasty
- Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 20 Years to 75 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Non-inflammatory Degenerative Joint Disease (NIDJD) of the Knee
- Interventions
- Journey™ II UNI Unicompartmental Knee System
- Device
- Lead sponsor
- Smith & Nephew, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Rockford, Illinois
- Conditions
- Colon Cancer
- Interventions
- Polyethylene Glycol afternoon, Polyethylene Glycol morning
- Drug
- Lead sponsor
- Cleveland Clinic Florida
- Other
- Eligibility
- Not listed
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Weston, Florida
- Conditions
- Crohn's Disease
- Interventions
- certolizumab pegol 400 mg, Placebo
- Biological · Other
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 51 more
- Conditions
- Multiple Sclerosis
- Interventions
- CNM-Au8
- Drug
- Lead sponsor
- Clene Nanomedicine
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Osteoarthritis, Knee, Arthritis, Rheumatoid
- Interventions
- total knee arthroplasty
- Device
- Lead sponsor
- DePuy Orthopaedics
- Industry
- Eligibility
- Up to 80 Years
- Enrollment
- 938 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 9
- States / cities
- Mobile, Alabama • Berkley, California • Fort Collins, Colorado + 6 more
- Conditions
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
- Interventions
- Panobinostat (LBH589), 5-Azacytidine
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 8
- States / cities
- Augusta, Georgia • Indianapolis, Indiana • Kansas City, Kansas + 5 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- ADI-PEG 20
- Drug
- Lead sponsor
- Polaris Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- New York, New York • Seattle, Washington
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- peginterferon alfa-2b, decitabine, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Leukemia, Acute Lymphoblastic Leukemia
- Interventions
- Rituximab, Cyclophosphamide (CTX), Doxorubicin, Vincristine, Dexamethasone, Methotrexate (MTX), Cytarabine, G-CSF, Mesna, Pegylated asparaginase, Pegfilgrastim, Solumedrol
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Crohn's Disease
- Interventions
- certolizumab pegol
- Biological
- Lead sponsor
- Atlanta Gastroenterology Associates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Adenoma Colon
- Interventions
- Simethicone Solution, Polyethylenglycol
- Drug · Other
- Lead sponsor
- Texas Tech University Health Sciences Center, El Paso
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 268 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- El Paso, Texas
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia
- Interventions
- Cyclophosphamide, Cytarabine, Dexamethasone, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Rituximab, Venetoclax, Vincristine
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- COVID-19
- Interventions
- Baricitinib, Dexamethasone, Placebo, Remdesivir
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1,010 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Fresno, California • La Jolla, California + 50 more
- Conditions
- Severe Alopecia Areata
- Interventions
- Ritlecitinib higher dose, Ritlecitinib lower dose
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Years to 14 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 22
- States / cities
- Irvine, California • Santa Ana, California • Aurora, Colorado + 17 more
- Conditions
- Ophthalmic Solutions
- Interventions
- F# 13418-148 Eye Drops, F#13418-158 Eye Drops, F# PF-004390 Eye Drops
- Drug
- Lead sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Autism Spectrum Disorder, Gastro-Intestinal Disorder, Constipation, Diarrhea
- Interventions
- vancomycin, Miralax, intestinal microbiota, placebo vancomycin, Miralax, placebo intestinal microbiota
- Combination Product
- Lead sponsor
- Arizona State University
- Other
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Tempe, Arizona